“100% successful” cancer drug gets landmark U.S. FDA approval
Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the U.S. Food and Drug Administration granted it Breakthrough Therapy Designation status. The drug, a programmed death receptor-1-blocking antibody, completely eradicated rectal cancer tumors without the need for surgery, radiation treatment, or chemotherapy. “Everyone on the clinical trial is doing great,” Memorial Sloan Kettering Cancer Center gastrointestinal oncologist Andrea Cercek said. “So far, 42 people have completed treatment, and all of them have no evidence of disease. Side effects were quite mild and well tolerated.”








